Duane Heinrichs, MD
Interventional Cardiology · Mesa, AZNPI 1356318539
Payments from drug & device makers
Across 76 payments — averaging $124.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abbott$2K
- Getinge USA Sales, LLC$145
- AstraZeneca$126
- Shockwave Medical, Inc$104
- Boston Scientific$80
- plus $261 from 7 others
What the payments were for
- Travel & lodging$6,74271%
- Food & beverage$2,74829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 35 | $7,238 |
| Abbott | 19 | $1,535 |
| Getinge USA Sales, LLC | 5 | $145 |
| AstraZeneca | 1 | $126 |
| Shockwave Medical, Inc | 1 | $104 |
| Boston Scientific | 4 | $80 |
| Bard Peripheral Vascular, Inc. | 2 | $78 |
| Heartflow, Inc. | 2 | $56 |
| Tactile Systems Technology Inc | 3 | $39 |
| Atricure, Inc. | 1 | $34 |
| Cvrx, Inc. | 1 | $22 |
| Venclose Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,490 in reported general payments places this provider in the 40th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 698 | $853,172 |
| XareltoRivaroxaban | 133 | $150,322 |
| Repatha SureclickEvolocumab | 116 | $81,270 |
| EntrestoSacubitril/Valsartan | 39 | $61,713 |
| Metoprolol Succinate | 747 | $9,280 |
| Flecainide Acetate | 180 | $9,098 |
| Valsartan | 167 | $5,307 |
| Atorvastatin Calcium | 546 | $5,069 |
| SotalolSotalol Hcl | 186 | $4,311 |
| Diltiazem 24hr ErDiltiazem Hcl | 114 | $3,722 |
| Losartan Potassium | 289 | $3,033 |
| Amlodipine Besylate | 487 | $2,839 |
| Rosuvastatin Calcium | 207 | $2,769 |
| Ezetimibe | 103 | $2,675 |
| Potassium Chloride | 135 | $2,566 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Mesa
- Nachiket PatelMesa$271K
- Jaskamal KahlonMesa$202K
- Alphonse AmbrosiaMesa$180K
- I-Hui ChiangMesa$165K
- Faraj KargoliMesa$115K
- Satya Prakash AtmakuriMesa$43K
- Robert CandipanMesa$33K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.